Comparison of Real-World Costs, Healthcare Resource Utilization, and Comorbidity-Related Costs Between Ixekizumab and Secukinumab Among Biologic-Experienced Patients with Psoriasis...

por Blauvelt, Andrew, Shi, Nianwen, Somani, Najwa, Burge, Russel, Zhu, Baojin, Ridenour, Terri, Kern, Scott, Lew, Carolyn, Zimmerman, Nicole, Murage, Mwangi
Publicado 2023

Healthcare Costs Among Patients with Psoriasis Treated with Ixekizumab Versus Secukinumab in Real-World Settings Over 24 Months

por Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Atiya, Bilal, Zhu, Baojin, Somani, Najwa, Ridenour, Terri, Lew, Carolyn R., Zimmerman, Nicole M., Murage, Mwangi J.
Publicado 2022

Comparison of Real-World Treatment Patterns Among Biologic-Experienced Patients with Psoriasis Treated with Ixekizumab or Secukinumab Over 18 Months

por Blauvelt, Andrew, Shi, Nianwen, Burge, Russel, Somani, Najwa, Ridenour, Terri L., Zhu, Baojin, Atiya, Bilal, Lew, Carolyn R., Zimmerman, Nicole M., Murage, Mwangi J.
Publicado 2021

Higher rates of skin clearance and efficacy in challenging body areas are associated with better health‐related quality of life following ixekizumab maintenance treatment in pediat...

por Hebert, Adelaide A., Bobonich, Margaret A., Rodriguez Capriles, Claudia, Gallo, Gaia, Li, Lingnan, Somani, Najwa, Ridenour, Terri, Wang, Yan, Edson‐Heredia, Emily, Becker, Emily M.
Publicado 2021